Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Atlassian Corporation PLC — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Atlassian Corporation PLC trades at $202 (market cap $52.66B). The key difference: Atlassian Corporation PLC is far larger — about 18.4× Dyne Therapeutics Inc. Common Stock's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Atlassian Corporation PLC for 65 Days on average.
| DYN | TEAM | |
|---|---|---|
Market Cap | $2.86B | $52.66B |
Volume | 3,341,579 | 2,601,329 |
Sector | Health | Technology |
52-Week High | $26.78 | $208.04 |
52-Week Low | $14.60 | $57.15 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $2.18B | $52.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Atlassian (TEAM) trades at $204.66, down 1.49% on the day, with a bullish technical signal from moving averages but overbought short-term RSI. The company shows strong revenue growth, improving net losses, and consistent earnings beats, though profitability metrics remain negative. Recent news highlights AI-driven growth catalysts and cloud momentum.
The outlook is positive given analyst consensus and AI adoption, but high valuation ratios and persistent net losses pose risks. Upside is supported by a large addressable market and subscription growth, while competition and execution challenges are key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
